In response to cold temperatures, the body adapts by restricting blood flow to the skin. This is done as a thermoregulating mechanism to prevent further loss of body heat and to sustain the core body temperature. In Raynaud phenomenon, blood-flow restriction occurs during cold temperatures and emotional stress. Specifically, in Raynaud phenomenon, there is vasoconstriction of the digital arteries and cutaneous arterioles. This phenomenon was first described by Maurice Raynaud in 1862 and later studied by Sir Thomas Lewis in 1930. Overall, Raynaud phenomenon is a transient and peripheral vasoconstrictive response to cold temperatures or emotional stress. Raynaud phenomenon can be categorized as either primary or secondary. 
Secondary Raynaud phenomenon is associated with different etiologies. It is most commonly associated with connective tissue disorders such as scleroderma, systemic lupus erythematosus, Sjogren syndrome, and antiphospholipid syndrome. 
Drugs, such as antimigraine medications, interferon alpha and beta, cyclosporine, and nonselective beta blockers, can cause secondary Raynaud phenomenon.
Occupations that result in overt vibrational exposure from vibrating machinery mostly affect males. This is known as hand-arm vibration syndrome. Exposure to polyvinyl chloride, cold injury from work, or ammunition work are other occupational-associated causes of secondary Raynaud phenomenon.
In the population of patients older than 60 years, the obstructive vascular disease is a frequent cause of Raynaud phenomenon. Obstructive vascular disease causes include thromboangiitis obliterans, microemboli, diabetic angiopathy, or atherosclerosis.
Infections associated with secondary Raynaud phenomenon include parvovirus B19, cytomegalovirus, hepatitis B, and hepatitis C.
Other causes of secondary Raynaud phenomenon include fibromyalgia, polycythemia, arteriovenous fistula, myalgic encephalitis, or malignancy.
Raynaud phenomena occur more frequently in women (about 20% to 30%), particularly in younger age populations (teens to 20s). The female to male ratio is 9 to 1. 
Three mechanisms contribute to Raynaud phenomena. These are decreased blood flow, blood vessels constriction, neurogenic responses, and inflammatory and immune responses.
The somatosensory system helps with temperature perception based on environmental stimuli. Afferent nerve fibers stimulated by cold temperatures activate A-delta and unmyelinated C-fibers. This eventually leads to activation of cold receptor TRPM8 (transient receptor potential ion channel) which monitors variations in cold temperatures. Activation of TRPM8 results in cutaneous vasoconstriction, thermogenesis, and avoidance of cold.
With cold temperatures, the sympathetic nervous system causes the release of vasoconstricting neuropeptides and norepinephrine leading to vasoconstriction of arteriole smooth muscle and decreased blood flood to the skin. Of note, in secondary Raynaud phenomena, endothelin-1 is released by endothelial cells which causes vasoconstriction.
In primary Raynaud phenomenon, an increase in alpha-2 adrenergic sensitivity in the digital and cutaneous vessels results in the vasoconstrictive response to cold temperatures and emotional stress. Alpha-2 adrenergic receptors are present on the distal arterial smooth muscles of the digits and affected by the sympathetic nervous system. Studies demonstrated that the use of alpha-2 adrenergic receptor inhibitors in patients with cold-induced attacks decreased the severity of the attack.
In secondary Raynaud phenomenon, the underlying disease is the factor that disrupts normal vessel reactivity to cold temperatures. Usually, the endothelial function of the digital and cutaneous vessels is compromised leading to eventual vasoconstriction with resulting tissue ischemia. For instance, fibrosis of the vascular system in systemic scleroderma leads to endothelial dysfunction followed by tissue ischemia.
In obtaining the history of a patient with suspected Raynaud phenomenon, clinicians should address the age of onset, the location of affected areas, the presence of symmetry, the presence of digital ulcerations, and severity of the attacks. The presence of other systemic symptoms should be elicited to rule out secondary Raynaud phenomena. Provoking factors should be identified once confirmed to be Raynaud phenomenon. Provoking factors may include exposure to cold temperatures or sympathetic nervous system stimulation from emotional stress or being startled. Certain factors increase the likelihood for increased frequency of attacks, increased severity with worse pain. These include the presence of stress, female gender, low temperature, and the presence of a concurrent connective tissue disease. The later the onset of Raynaud phenomenon, particularly in the 30s and 40s age range, the higher the risk of the development of a connective tissue disorder.
Raynaud phenomena typically affect fingers (distal areas). A Raynaud phenomenon attack is sudden with the development of cold digits and the demarcation of "white" areas also known as skin pallor or white attack. Instead of white attack, there may be cyanotic skin changes, otherwise known as a blue attack. The white or blue attack typically remains for approximately 20 minutes. After the Raynaud phenomenon flare, vascular reperfusion with subsequent rewarming occurs. This results in erythematous areas where the flare occurred. It is known as reactive hyperemia.
A Raynaud phenomenon attack starts out with a single digit and then spreads to other digits symmetrically on both hands. The thumb is typically spared. If the thumb is affected, this may be a sign of secondary Raynaud phenomenon. It may also result in cutaneous vasospasm affecting facial areas, ears, knees, or nipples.
As a result of vasoconstriction, pin and needles sensation, numbness or finger aches or pain are common complaints with Raynaud phenomenon attacks. If the Raynaud phenomenon attack is severe, typically with secondary Raynaud phenomenon, digital ulceration of the tips of fingers and toes may occur due to prolonged vasoconstriction with subsequent tissue ischemia. Eventual gangrene or loss of digits may occur in severe forms of Raynaud phenomenon attacks. In general, Raynaud phenomenon attacks are less severe in primary Raynaud phenomenon compared to secondary Raynaud phenomenon.
Another skin finding seen during a Raynaud phenomenon attack is livedo reticularis. This results in purplish mottling or reticular pattern over the skin due to small blood vessel clots. This finding is reversible with rewarming but is irreversible with secondary causes, such as antiphospholipid syndrome, vasculitis, cold agglutinin disease, or peripheral vascular disease.
Nailfold capillary microscopy is utilized as a diagnostic method to differentiate primary Raynaud phenomena from secondary Raynaud phenomenon. It analyzes microvascular and morphologic changes in peripheral vessels seen with CTD, such as changes in architecture, capillary size, capillary density, the presence of hemorrhage, and avascular areas without capillary loops. This is done using a dermatoscope or ophthalmoscope. Nailfold videocapillaroscopy can also be used. Abnormal nail-fold microscopy is correlated with an increased likelihood of the development of CTD. The changes were seen are capillary loops appear enlarged or there is a loss of capillary loops. If there are mega-capillaries with a decreased capillary density, then these changes are indicative of scleroderma. 
Treatment of Raynaud phenomenon aims at decreasing the frequency and severity of the attacks with prevention of tissue ischemia. Treatment response is measured by the Raynaud Condition Score (RCS). This scoring system looks at the quality of life, frequency and severity of attacks, and the effect of Raynaud phenomenon on an individual. 
Conservative medical management to prevent Raynaud phenomenon attacks is a lifestyle change. This includes avoiding exposure to cold, staying warm, avoiding stimulants, avoiding anxiety or emotional stress, and smoking cessation.
If the patient fails to respond to only conservative therapy, then pharmacologic therapy with a vasodilating mechanism of action is used. Dihydropyridine calcium channel blockers (DHP CCBs) are the first-line pharmacologic treatment for Raynaud phenomenon. DHP CCBs include amlodipine and nifedipine. When starting CCBs, the medication is started at the lowest dose and gradually titrated every 4 weeks depending on the patient's response. Monitoring blood pressure response is important, particularly if the patient has baseline blood pressures that are low.
1. Amlodipine dosage: Minimum 5 mg to maximum 20 mg daily
2. Nifedipine dosage: Minimum 30 mg to maximum 180 mg daily
The medication may be administered as either slow-release form, rapid or short-acting form, or long-acting form. Typically, the slow-release or long-acting forms of CCBs are used. An urgent situation prompts the use of a rapid, short-acting form of CCB, which is used more frequently in patients with severe form of Raynaud phenomenon.
Adverse effects of DHP CCB includes dose-related peripheral edema, palpitations, reflex tachycardia, dose-related dizziness, and headaches.
Contraindications to DHP CCB are hypotension, peripheral edema, angina, myocardial infarction. It should also be avoided in patients with severe aortic stenosis, hypertrophic cardiomyopathy, and severe pulmonary hypertension.
CCBs should be avoided in pregnancy unless digit ischemia is present.
If the patient fails to respond to DHP CCB therapy, a phosphodiesterase (PDE) inhibitor. It can be added to the current CCB therapy if partial treatment response is noted to the CCB. If there is no treatment response to the CCB, then the PDE inhibitor can be used as monotherapy. Sildenafil is started at a low dose, 20 mg daily, and then titrated depending on response over a period of 4 to 6 weeks with a maximum dose of 20 mg 3 times a day.
Alternative therapy to treatment failure using CCB and PDE inhibitor is topical nitrates, such as nitroglycerin, which is a direct vasodilator. Typically, 2% nitroglycerin ointment is used and applied to affected Raynaud phenomenon areas. Topical nitrates are absorbed systemically and may result in adverse systemic effects, such as hypotension, dizziness, and headache.
Other options, if the patient does not respond to the above therapies, include the following: losartan, fluoxetine, and prazosin.
If tissue ischemia is present in the digits and symptoms are severe, then intravenous infusion of prostaglandin is used. Different intravenous prostaglandins include iloprost, epoprostenol, treprostinil, and alprostadil. Prostaglandin functions as a strong vasodilator and also prevents platelet cell aggregation.
Bosentan blocks endothelin-1 vasoconstrictive effect. This is used in recurrent digit ulceration in CTD, such as systemic sclerosis. Surgery to remove the particular sympathetic nerves that cause vasoconstriction, also known as sympathectomy, can be used in severe, refractory cases.
In the setting of secondary Raynaud phenomenon and history of ischemic ulceration, low dose aspirin 81 mg should be used daily. If there is aspirin intolerance or contraindication, clopidogrel, or dipyridamole can be used instead.
There are different conditions or disease that appear similar to Raynaud phenomenon. This includes the following external blood vessel compression, complex regional pain syndrome, erythromelalgia, acute idiopathic blue finger also known as paroxysmal finger hematoma, acrocyanosis, occlusive peripheral vascular disease, peripheral neuropathy, and excessive cold sensitivity.
With primary Raynaud phenomenon, spontaneous remission, whereby the patient has been free of Raynaud phenomenon attacks, may occur. Spontaneous remission is not seen with secondary Raynaud phenomenon. Pregnancy has been shown to improve Raynaud phenomenon since there is an improvement in peripheral blood flow and oxygenation due to increase in red blood cell mass and plasma volume.
Severe Raynaud phenomenon may result in tissue ischemia, leading to necrosis followed by amputation of the affected area.
Vascular surgery consult is needed for sympathectomy. A primary care physician can treat primary Raynaud phenomenon. Rheumatology should be consulted if there is secondary Raynaud phenomenon.
an interprofessional approach to Raynaud phenomenon
Raynaud phenomenon is best managed with an interprofessional team of healthcare professionals. The key to improving the morbidity is education. Besides the physician, the nurse and the pharmacist are in a prime position to educate the patient about the hazards of smoking. In addition, patients have to be told to insulate their hands and fingers from the cold. The pharmacists must make sure that the patient is on no medication that can cause vasoconstriction of the blood vessels. When ulcers develop the patient should be told to seek medical help as soon as possible to avert gangrene. A wound care nurse should be consulted on educating the patient on the care of the wounds and the type of dressings to use. A dietary consult is recommended as there is some evidence that a diet rich in omega 3-fatty acids may be beneficial in preventing Raynaud phenomenon. (Level V)
The prognosis for patients with primary Raynaud phenomenon in young people is good with little morbidity or mortality. However, if the patient does not change lifestyle or smokes, then ischemia may affect the distal tips of the fingers and lead to necrosis. There are reports that in the elderly population with Raynaud phenomenon, the risk of adverse cardiac events may be increased compared to the general population. For patients with secondary Raynaud phenomenon, the prognosis depends on the underlying disorder. In general, the quality of life for these patients is poor as they need to adopt a rigid lifestyle. Plus, many other secondary causes often have no cures and relapses are common. [Level 5]
|||Ventura I,Reid P,Jan R, Approach to Patients with Suspected Rheumatic Disease. Primary care. 2018 Jun [PubMed PMID: 29759118]|
|||Pauling JD,Reilly E,Smith T,Frech TM, Evolving symptoms of Raynaud's phenomenon in systemic sclerosis are associated with physician and patient-reported assessments of disease severity. Arthritis care [PubMed PMID: 30133174]|
|||Fernández-Codina A,Walker KM,Pope JE, Treatment algorithms for systemic sclerosis according to experts. Arthritis [PubMed PMID: 29781586]|
|||Wollina U,Koch A,Langner D,Hansel G,Heinig B,Lotti T,Tchernev G, Acrocyanosis - A Symptom with Many Facettes. Open access Macedonian journal of medical sciences. 2018 Jan 25 [PubMed PMID: 29484025]|
|||Ruaro B,Sulli A,Smith V,Pizzorni C,Paolino S,Alessandri E,Cutolo M, Microvascular damage evaluation in systemic sclerosis: the role of nailfold videocapillaroscopy and laser techniques. Reumatismo. 2017 Dec 21 [PubMed PMID: 29320840]|
|||Belch J,Carlizza A,Carpentier PH,Constans J,Khan F,Wautrecht JC,Visona A,Heiss C,Brodeman M,Pécsvárady Z,Roztocil K,Colgan MP,Vasic D,Gottsäter A,Amann-Vesti B,Chraim A,Poredoš P,Olinic DM,Madaric J,Nikol S,Herrick AL,Sprynger M,Klein-Weigel P,Hafner F,Staub D,Zeman Z, ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. VASA. Zeitschrift fur Gefasskrankheiten. 2017 Oct [PubMed PMID: 28895508]|
|||Ingegnoli F,Ughi N,Dinsdale G,Orenti A,Boracchi P,Allanore Y,Foeldvari I,Sulli A,Cutolo M,Smith V,Herrick AL, An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey). Rheumatology international. 2017 Nov [PubMed PMID: 28894946]|
|||Lee KA,Chung HW,Lee SH,Kim HR, The use of hand perfusion scintigraphy to assess Raynaud's phenomenon associated with hand-arm vibration syndrome. Clinical and experimental rheumatology. 2017 Sep-Oct [PubMed PMID: 28664836]|
|||Vidal C,Ruano C,Bernardino V,Lavado Carreira P,Lladó A,Santos MC,Gruner H,Panarra A,Riso N,Moraes-Fontes MF, Clinical Presentation and Long-Term Outcomes of Systemic Sclerosis Portuguese Patients from a Single Centre Cohort: A EUSTAR Registration Initiative. Acta medica portuguesa. 2018 Jun 29 [PubMed PMID: 30020876]|
|||Ingegnoli F,Ughi N,Crotti C,Mosca M,Tani C, Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis. Swiss medical weekly. 2017 [PubMed PMID: 28975961]|
|||Mirbod SM,Sugiura H, A non-invasive technique for the evaluation of peripheral circulatory functions in female subjects with Raynaud's phenomenon. Industrial health. 2017 Jun 8 [PubMed PMID: 28321017]|
|||Daniels J,Pauling JD,Eccelston C, Behaviour change interventions for the management of Raynaud's phenomenon: a systematic review protocol. BMJ open. 2017 Aug 4 [PubMed PMID: 28780561]|
|||Pain CE,Constantin T,Toplak N,Moll M,Iking-Konert C,Piotto DP,Aktay Ayaz N,Nemcova D,Hoeger PH,Cutolo M,Smith V,Foeldvari I, Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clinical and experimental rheumatology. 2016 Sep-Oct [PubMed PMID: 27494080]|
|||Pope J,Harding S,Khimdas S,Bonner A,Baron M, Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. The Journal of rheumatology. 2012 Mar [PubMed PMID: 22247347]|
|||Klein-Weigel P,Opitz C,Riemekasten G, Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. VASA. Zeitschrift fur Gefasskrankheiten. 2011 Jan [PubMed PMID: 21283969]|
|||Herrick AL, Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Current opinion in rheumatology. 2011 Nov [PubMed PMID: 21885977]|
|||Hinchcliff M,Varga J, Systemic sclerosis/scleroderma: a treatable multisystem disease. American family physician. 2008 Oct 15 [PubMed PMID: 18953973]|
|||Herrick AL, Advances in palliative care for the patient with scleroderma. Current opinion in rheumatology. 1996 Nov [PubMed PMID: 9018459]|
|||Curtiss P,Schwager Z,Cobos G,Lo Sicco K,Franks AG Jr, A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon. Journal of the American Academy of Dermatology. 2018 Jun [PubMed PMID: 29408338]|
|||Rirash F,Tingey PC,Harding SE,Maxwell LJ,Tanjong Ghogomu E,Wells GA,Tugwell P,Pope J, Calcium channel blockers for primary and secondary Raynaud's phenomenon. The Cochrane database of systematic reviews. 2017 Dec 13 [PubMed PMID: 29237099]|